GlobeNewswire by notified

Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome

Share

PRESS RELEASE

December28, 2021

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the initiation of a Phase 2b clinical trial of Tesomet in patients with Prader-Willi syndrome (PWS). Tesomet is an investigational fixed-dose combination therapy of tesofensine, a triple monoamine reuptake inhibitor, and metoprolol, a beta-1 selective blocker. Data from the trial are expected in the first half of 2023.

“The initiation of this Phase 2b clinical trial of Tesomet in Prader-Willi syndrome follows our recent initiation of a Phase 2b clinical trial of Tesomet in hypothalamic obesity – two serious diseases with high unmet need,” said Rudolf Baumgartner, M.D., Chief Medical Officer and Head of Clinical Development at Saniona. “In addition to these two trials, we are also conducting a Phase 1 clinical trial of SAN711, which means Saniona is ending 2021 with three clinical trials ongoing. This is a significant achievement and represents the hard work and expertise of our clinical, regulatory, technical operations and quality teams.”

The Phase 2b clinical trial in PWS includes a randomized, double-blind, placebo-controlled 16-week treatment period followed by a 36-week open-label extension period. The trial is expected to enroll approximately 120 patients with genetically-confirmed PWS. Initially, the trial will enroll adults (18 to 65 years of age) and then, following confirmation by the data monitoring committee and by the FDA, the trial is planned to expand into adolescents (13 to 17 years of age). During the 16-week double-blind period, participants will be randomized to receive daily dosing with Tesomet at one of three dose levels or a placebo. During the 36-week open-label extension period, participants who wish to continue treatment, including those who originally received placebo, will receive the highest tolerated dose of Tesomet as established during the double-blind period. The primary objective of the study will be change in hyperphagia at week 16 as measured by the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), a caregiver-reported survey that evaluates food-seeking behavior, such as frequency of sneaking food or time spent talking about food, and which has been used as the primary outcome measure for most PWS clinical trials. Secondary endpoints include change in body weight, change in caregiver impression of hyperphagia, change in clinician impression of overall disease severity, and change in clinician impression of overall clinical status.

The clinical trial is being conducted at multiple sites around the world including in the United States, New Zealand, Australia, and in multiple countries in Europe including the United Kingdom, Sweden, Italy, Spain and others. More information is available at www.praderwillisyndromestudy.com or www.clinicaltrials.gov.

“Currently, there are no approved treatments for hyperphagia, the uncontrollable hunger that is one of the most debilitating symptoms of PWS,” said Paige Rivard, CEO of Prader-Willi Syndrome Association USA. “We are encouraged to see Saniona addressing hyperphagia, and we look forward to working with them to support this clinical trial through education and outreach amongst our community.”

“As a physician scientist with over 40 years of clinical practice experience, I have researched PWS extensively and cared for many patients and families afflicted by this disorder,” said Merlin G. Butler, M.D., Ph.D., Professor of Psychiatry, Behavioral Sciences and Pediatrics, and Director of the Division of Research and Genetics and the KUMC Genetics Clinic at the University of Kansas Medical Center. “The complex presentation of PWS has made it a difficult target for drug developers, but I am encouraged by the initial Tesomet data and look forward to the data from this clinical trial.”

Saniona previously evaluated Tesomet in a randomized, double-blind, placebo-controlled initial Phase 2 trial in adults and adolescents with PWS. Adult patients receiving Tesomet achieved a statistically significant reduction in hyperphagia, as well as a reduction in body weight. Adolescent patients demonstrated dose-dependent reductions in hyperphagia and body weight in open-label extensions of the study. Tesomet received orphan drug designation in PWS from the FDA, who also confirmed that Tesomet may be advanced via the 505(b)(2) regulatory pathway. Saniona is partnering with the Foundation for Prader-Willi Research (FPWR), the Prader-Willi Syndrome Association USA (PWSA-USA), and the International Prader-Willi Syndrome Organisation (IPSWO) to inform the clinical trial design and clinical development processes, and to raise awareness within the PWS community.

Saniona is also evaluating Tesomet in a Phase 2b clinical trial for hypothalamic obesity (HO). The FDA granted Tesomet orphan drug designation in HO in July 2021.

For more information, please contact
Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: trista.morrison@saniona.com

The information was submitted for publication, through the agency of the contact person set out above, at 17:00 CET on 28December2021.

About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for patients suffering from rare diseases for which there are a lack of available treatment options. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, serious rare disorders characterized by severe weight gain, disturbances of metabolic functions and uncontrollable hunger. Saniona has developed a proprietary ion channel drug discovery engine anchored by IONBASE™, a database of more than 130,000 compounds, of which more than 20,000 are Saniona’s proprietary ion channel modulators. Through its ion channel expertise, Saniona is advancing two wholly-owned ion channel modulators, SAN711 and SAN903. SAN711 is in a Phase 1 clinical trial and may be applicable in the treatment of rare neuropathic disorders, and SAN903 is in preclinical development for rare inflammatory, fibrotic and hematological disorders. Led by an experienced scientific and operational team, Saniona has an established research organization in the Copenhagen area, Denmark, and a corporate office in the Boston, Massachusetts area, U.S. The company’s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at http://www.saniona.com.

About Tesomet
Tesomet is an investigational fixed-dose combination therapy of tesofensine (a triple monoamine reuptake inhibitor) and
metoprolol (a beta-1 selective blocker). Saniona is advancing Tesomet for hypothalamic obesity and Prader-Willi
syndrome, two serious rare disorders characterized by severe weight gain, disturbances of metabolic functions and uncontrollable hunger. The programs are currently in clinical development. Saniona holds worldwide rights to Tesomet and is actively evaluating opportunities to advance this treatment globally.

About Prader-Willi Syndrome (PWS)
Prader-Willi syndrome (PWS) is a rare genetic condition that results in a variety of symptoms. Patients often experience hyperphagia, an uncontrollable hunger, and may display abnormal food seeking behavior such as stealing food. Additional symptoms include abnormal growth and body composition; low muscle tone or hypotonia; and social, emotional, or cognitive deficits. Hyperphagia is reported by caregivers to be among the most worrisome aspects of PWS, as this insatiable hunger persists no matter how much the patients eat and often requires caregivers to install locks on refrigerators and food storage areas. Many of those affected with PWS become obese and suffer shortened life expectancy and significant mortality. Common causes of mortality in PWS include respiratory and cardiac failure, infection, choking, gastric rupture, and pulmonary embolism. There are no medications approved specifically for the hyperphagia associated with PWS, and there is no cure for this disease. Current treatment depends on symptoms and often includes hormone replacement, including growth hormone. PWS is estimated to impact between 11,000 and 34,000 patients in the U.S. and between 17,000 and 50,000 patients in Europe.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Share Buyback Transaction Details January 20 – 26, 202227.1.2022 10:00:00 CET | Press release

Share Buyback Transaction Details January 20 – 26, 2022 January 27, 2022 - Wolters Kluwer today reports that it has repurchased 78,099 of its own ordinary shares in the period from January 20, 2022, up to and including January 26, 2022, for €6.9 million and at an average share price of €88.92. These repurchases are part of the share buyback program announced on November 3, 2021, under which we intend to repurchase shares for €50 million during the period starting January 3, 2022, up to and including February 21, 2022. The cumulative amounts repurchased to date under this program are as follows: Share Buyback 2022 PeriodCumulative shares repurchased in period Total consideration (€ million)Average share price (€) 2022 to date 265,483 25.0 94.18 For the above-mentioned period, we have engaged a third party to execute €50 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company’s Articles of Association.

Cool Company Limited Update27.1.2022 09:14:12 CET | Press release

27 January 2022; Golar LNG (“Golar”) is pleased to provide a further update on the formation of Cool Company Ltd. (“CoolCo”). Reference is made to announcements on 15 December 2021 and 20 January 2022, regarding Golar’s announced execution of a Terms Agreement to separate its 8 TFDE LNG carriers into CoolCo. Based on investor feedback following the press releases made on 15 December 2021 and 20 January 2022, CoolCo has decided to launch a book building process of a private placement of $250 million (“The Private Placement”). The anticipated proceeds from the Private Placement will, together with a contemplated debt refinancing, be used to finance the acquisition of the 8 TFDE vessels from Golar, secure attractive financing and provide CoolCo with working capital to position the company for further growth. Eastern Pacific Shipping (“EPS”) has pre-subscribed and guaranteed an allocation of minimum $150 million in the contemplated private placement. The Private Placement The Private Place

Hitachi Energy achieves 100% fossil free electricity in own operations27.1.2022 09:00:00 CET | Press release

The global technology and market leader in power grids has achieved the first-step target in its Sustainability 2030 plan and steps up the pace towards carbon-neutral Zurich, Switzerland, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Hitachi Energy today announced that it has achieved the first-step target set out in its Sustainability 2030 plan – the use of 100% fossil-free electricity in its own operations1. The company is driving towards being carbon-neutral in its own operations by 20302, in line with its Purpose, ‘Advancing a sustainable energy future for all’. “By achieving 100% fossil-free electricity in our own operations, we have reduced our CO2 equivalent emissions by over 50% compared to 2019,” says Claudio Facchin, CEO of Hitachi Energy. He continued, “The Net Zero challenge is global and it’s about acting now, innovating and collaborating across countries, industries and societies. Together with customers, partners, and all stakeholders, we are advancing the world’s energy system to b

Participation notification by Blackrock Inc.27.1.2022 08:30:00 CET | Press release

Participation notification by Blackrock Inc. Brussels, 27 January 2022, 08:30 CET - According to Belgian transparency legislation (Law of May 2, 2007), BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.) recently sent to Solvay the following transparency notifications indicating that it crossed the threshold of 3%. Here is a summary of the moves: Date on which the threshold was crossed Voting rights after the transaction Equivalent financial instruments after the transaction Total January 21, 2022 3.05% 0.41% 3.46% January 24, 2022 2.93% 0.44% 3.37% The latest notification, dated January 25, 2022, contains the following information: Reason for the notification: acquisition or disposal of voting securities or voting rightsNotified by: BlackRock Inc. (55 East 52nd Street, New York, NY, 10055, U.S.A.)Date on which the threshold is crossed: January 24, 2022Threshold of direct voting rights crossed: 3% downwardsDenominator: 105,876,416Additional information: The disclosure obl

Van Lanschot Kempen prepares additional covered bond programme27.1.2022 08:30:00 CET | Press release

’s-Hertogenbosch/Amsterdam, the Netherlands, 27January 2022 Van Lanschot Kempen is working on creating an additional covered bond programme with a soft bullet structure in 2022, under which any future covered bonds are expected to be issued. The new programme will allow further diversification of Van Lanschot Kempen’s debt investor base and funding profile. Media Relations: +31 203544585; mediarelations@vanlanschotkempen.com Investor Relations: +31 203544590; investorrelations@vanlanschotkempen.com About Van Lanschot Kempen Van Lanschot Kempen, a wealth manager active in Private Banking, Asset Management and Merchant Banking, aims to preserve and create wealth, in a sustainable way, for both its clients and the society of which it is part. Listed at Euronext Amsterdam, Van Lanschot Kempen is the Netherlands’ oldest independent financial services company, with a history dating back to 1737. For more information, please visit vanlanschotkempen.com This press release does not constitute a

Stolt-Nielsen Limited Reports Unaudited Results For the Fourth Quarter and Full Year 202127.1.2022 08:15:00 CET | Press release

LONDON, January 27, 2022 – Stolt-Nielsen Limited (Oslo Børs: SNI) today reported unaudited results for the fourth quarter and full year 2021. The Company reported a fourth-quarter net profit of $35.0 million, with revenue of $593.1 million, compared with a net profit of $33.5 million, with revenue of $580.9 million, in the third quarter. The net profit for the full year 2021 was $78.8 million, with revenue of $2,181.1 million, compared with a net profit from continuing operations of $39.2 million, with revenue of $1,955.1 million, in 2020. Highlights for the fourth quarter, compared with the third quarter of 2021, were: Stolt Tankers reported operating profit of $19.2 million, down from $24.1 million due to weaker COA volumes and rising voyage expenses. The Stolt Tankers Joint Service (STJS) Sailed-in Time-Charter Index reduced slightly from 0.53 to 0.51. The STJS sailed-in revenue for the quarter was $18,438 per operating day basis an average size per ship of 31,694 deadweight tonnes

PGS ASA: Q4 and Preliminary Full Year 2021 Results27.1.2022 08:00:00 CET | Press release

Improving Competitive Position in a Gradually Recovering Market Takeaways 2021 Segment Revenues and Other Income of $590.0 million, compared to $595.9 million in 2020, which included $38.8 million of Covid-19 related government grantsSegment EBITDA of $320.2 million, compared to $397.7 million in 2020, impacted by a significant change of activity mix with less MultiClient and more contract acquisitionSegment EBIT loss (excluding impairments and other charges) of $54.6 million, compared to a profit of $12.2 million in 2020Cash flow from operations of $326.6 million, compared to $366.5 million in 2020Returning to positive net cash flow generation in 2021, with cash flow before financing activities (interest payments and debt service) of $154.7 million for the full year As Reported Revenues and Other Income according to IFRS of $703.8 million and an EBIT loss of $66.2 million, compared to $512.0 million and an EBIT loss of $188.0 million, respectively, in 2020Leveraging PGS’ integrated bu